Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease

References

• Devita V. T. The consequences of chemotherapy of Hodgkin's disease: the 10th David A. Karnofsky Memorial Lecture. Cancer 1987; 47: 1–13
   Web of Science ®Google Scholar
• Milstein C., Cuello A. C. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305: 537–540
   PubMed Web of Science ®Google Scholar
• Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 1995; 145: 179–209
   PubMed Web of Science ®Google Scholar
• Hombach A., Jung W., Pohl C., Renner C., Sahin U., Schmits R., Wolf J., Kapp U., Diehl V., Pfreundschuh M. CD16/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer 1993; 55: 830–837
   PubMed Web of Science ®Google Scholar
• Pohl C., Denfeld R., Renner C., Jung W., Bohlen H., Sahin U., Hombach A., Van Lier R., Schwonzen M., Diehl V., Pfreundschuh M. CD30-antigen-specific targeting and activation of T-cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer 1993; 54: 820–827
   PubMed Web of Science ®Google Scholar
• Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trümper L., Hartmann F., Diehl V., Van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833–835
   PubMed Web of Science ®Google Scholar
• Falini B., Piled S., Pizzolo G., Diirkop H., Flenghi L., Stirpe E., Martelli M. E, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Hartmann E., Renner C., Jung W., Deisting C., Juwana M., Eichentopf B., Kloft M., Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD 16/CD30 bispecific antibody. Blood 1997; 89: 2042–2047
   PubMed Web of Science ®Google Scholar
• Investigator's handbook. A Manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program. DCT, NCI, Bethesda, MD 1993, 20892, USA
   Google Scholar
• Pohl C., Renner C., Schwonzen M., Sieber M., Lorenz P., Pfreundschuh M., Diehl V. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies. Int. J. Cancer 1992; 50: 958–967
   PubMed Web of Science ®Google Scholar
• Blomberg K., Ulfstedt A. C. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J. Immunol. Meth. 1993; 160: 27–38
   PubMed Web of Science ®Google Scholar
• Bolhuis R. L., Lamers C. H., Goey S. H., Eggermont A. M., Trimbos J. B., Stoter G., Lanzavecchia A., Di Re E., Miotti S., Raspagliesi E., Rivoltini L., Colnaghi M. I. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer 1992; 78(Suppl 7)78–81
   Google Scholar
• Canevari S., Stoter G., Arienti E., Bolis G., Colnaghi M. I., Di Re E. M., Eggermont A. M.M., Goey S. H., Gratama J. W., Lamers C. H.J., Nooy M. A., Parmiani G., Raspagliesi E., Ravagnani E., Scarfone G., Trimbos J. B., Warnaar S. O., Bolhuis R. L.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 1995; 87: 1463–1469
   PubMed Web of Science ®Google Scholar
• De Gast G. C., Haagen I. A., Van Houten A. A., Klein S. C., Duits A. J., De Weger R. A., Vroom T. M., Clark M. R., Phillips S., Van Dijk A. J., Bast B. J.H. CDS T cell activation after intravenous administration of CD3xCDl9 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 1995; 40: 390–396
   PubMed Web of Science ®Google Scholar
• Kroesen B. J., Ter Haar A., Spakman H., Willemse P., Sleijfer D. T., De Vries E. G., Mulder N. H., Berendsen H. H., Limburg P C, The T. H., De Leij L. Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody redirected T cells. Cancer Immunol. Immunother. 1993; 37: 400–407
   PubMed Web of Science ®Google Scholar
• Kroesen B. J., Buter J., Sleijfer D. T., Janssen R. A., Van Der Graaf W. T., The T. H., De Leij L., Mulder N. H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 1994; 70: 652–661
   PubMed Web of Science ®Google Scholar
• Nitta T., Sato K., Yagita H., Okumura E., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368–371
   PubMed Web of Science ®Google Scholar
• Tibben J. G., Boerman O. C., Massuger L. E, Schijf C. P., Claessens R. A., Corstens E H. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int. J. Cancer 1996; 66: 477–483
   PubMed Web of Science ®Google Scholar
• Valone F. H., Kaufman P. A., Guyre P. M., Lewis L. D., Memoli V., Deo Y., Graziano R., Fisher J. L., Meyer L., Mrozek-Orlowski M., Wardwell K., Guyre V., Morley T. L., Arvizu C., Fanger M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu.X. Clin. Oncol. 1995; 13: 2281–2292
   Web of Science ®Google Scholar
• Curnow R. T., Pfister D. G., Deo Y., Motzer R. J., Winston C., Keeperman K. L., Malone T. A phase I trial of bispecific antibody (BsAB) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumors. Proc. Am. Soc. Clin. Oncol. 1997; 16: 1571, abstract
   Google Scholar
• Weiner L. M., Clark J. I., Davey M., Li W. S., De Palazzo I. G., Ring D. B., Alpaugh R. K. Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FCγRIII. Cancer Res. 1995; 55: 4586–4593
   PubMed Web of Science ®Google Scholar
• Clark J. I., Alpaugh R. K., Von Mehren M., Schultz J., Gralow J. R., Cheever M. A., Ring D. B., Weiner L. M. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol. Immunother. 1997; 44: 265–272
   PubMed Web of Science ®Google Scholar
• Lamers C. H.J., Gratama I. W., Warnaar S. O., Stoter G., Bolhuis R. L.H. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAB-targeted activated T-lymphocytes. Int. J. Cancer 1995; 60: 450–457
   PubMed Web of Science ®Google Scholar
• Hartmann R., Renner C., Tembrink S., Held G., Ames M., Jung W., Pfreundschuh M. Treatment of refractory Hodgkin's disease (HD) with an and- CD30/CD16 bispecific monoclonal antibody (BiMAb). Proc. Am. Soc. Clin. Oncol. 1998; 17: 60, abstract
   Google Scholar
• Holliger P., Prospero T., Winter G. Diabodies: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993; 90: 6444–6448
   PubMed Web of Science ®Google Scholar
• Mack M., Riethmüller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 1995; 92: 7021–7025
   PubMed Web of Science ®Google Scholar